IDEAYA Biosciences Inc at Jefferies London Healthcare Conference Transcript
Hi everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Yujiro Hata, the CEO of IDEAYA Biosciences. Thanks so much for joining us today, Yujiro, in London.
Yeah, Maury, thanks for the kind introduction, and thank you for Jefferies again for the invitation. Great to be back here in London with everyone back in person. So thank you.
Questions & Answers
And we'll do a fireside chat. So maybe to start off, if you can provide a one-minute intro highlighting your main clinical candidates and key catalysts ahead?
Sure. So today, we have two programs in the clinic, darovasertib, which is in Phase 2. We recently presented a fairly robust Phase 2 efficacy data set in combination with Pfizer's quizartinib. The key catalysts for that program upcoming
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
